Chemotherapy has historically been the mainstay of cancer treatment, but our
understanding of what drives a successful therapeutic response remains limited. The …

Over the past five years, oxygen-based nanocarriers (NCs) to boost anti-tumor therapy
attracted tremendous attention from basic research and clinical practice. Indeed, tumor …

Chemoresistance to platinums, such as cisplatin, is of critical concern in the treatment of
ovarian cancer. Recent evidence has linked epithelial–mesenchymal transition (EMT) as a …

Objective Cisplatin is a widely used gastric cancer (GC) chemotherapy; however, genetic
factors regulating GC responses to cisplatin remain obscure. Identifying genes regulating …

Epithelial ovarian cancer is the leading cause of death among gynecologic malignancies.
Diagnosis usually occurs after metastatic spread, largely reflecting vague symptoms of early …

Purpose Ovarian cancer has a high mortality rate and up to now no reliable molecular
prognostic biomarkers have been established. During malignant progression, the …

Abstract PD‐1/PD‐L1 inhibitors have emerged as standard treatments for advanced solid
tumors; however, challenges such as a low overall response rate and systemic side effects …

The lethality of epithelial ovarian cancer (OC) is largely due to a high rate of recurrence and
development of chemoresistance, which requires synergy between cancer cells and the …

Abstract Effects of Chk1 and MEK1/2 inhibition were investigated in cytokinetically quiescent
multiple myeloma (MM) and primary CD138+ cells. Coexposure to the Chk1 and MEK1/2 …

[Gd (OH)] 2+[(SN-38) 0.5 (FdUMP) 0.5] 2− inorganic–organic hybrid nanoparticles (IOH-
NPs) with a chemotherapeutic cocktail of ethyl-10-hydroxycamptothecin (SN-38, active form …